# Moyang Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/moyang-biotechnology

- Industry: Materials
- Headquarters: Shanghai, China
- Website: www.mybiotec.cn
- Total disclosed funding: $14M
- Latest round: Series B (Nov 15, 2024)
- Investors on record: 4

## About

Established in 2018 and based in Shanghai, China, Moyang Biotechnology operates as a medical beauty material developer specializes in biotechnological solutions. In August 2025, it closed a round of venture funding. Moyang Biotechnology specializes in the development and provision of innovative biotechnological products and solutions. It focuses on a core lineup of offerings that include biochemical reagents and diagnostic kits, which are primarily designed for use in medical laboratories and research institutions. Products include medical devices, cosmetic fillers, and skin care products. Medical devices are sterile liquid wound dressings. Cosmetic fillers include facial fillers and collagen fillers. Products can be used in orthopaedics, oral and maxillofacial surgery, neurosurgery, and other fields. The company generates revenue through a structured business model that primarily involves B2B transactions with healthcare providers and research institutions. The company engages in direct sales of its flagship products, including proprietary diagnostic kits and biochemical reagents. The company will use the fund raised from the latest round to expand its marketing team, increase global market coverage, accelerate next-generation product R&D, and advance its industrialization plans in the regenerative aesthetic medicine sector.

## Funding rounds

- Series B, Nov 15, 2024, $14M — Jinding Capital, BioTrack Capital, Hengxu Capital, Yanbei Capital

## Investors

- Jinding Capital (https://capitalatlas.ai/funds/jinding-capital) — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B
- Hengxu Capital (https://capitalatlas.ai/funds/hengxu-capital) — Series B
- Yanbei Capital — Series B